ArticleThe Journal of clinical investigation2007
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance.
Article in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 105 citations in OpenAlex.
- Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.British journal of haematology · 2020Trial
- FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009Trial
- Activated B-Cells enhance epitope spreading to support successful cancer immunotherapy.Frontiers in immunology · 2024Review
- An immune-based tool platform for in vivo cell clearance.Life science alliance · 2023Article
- CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy.Science advances · 2022Article
- The link between circulating follicular helper T cells and autoimmunity.Nature reviews. Immunology · 2022Review
- Nanomedicines in B cell-targeting therapies.Acta biomaterialia · 2022Review
- Differences of Circulating CD25Journal of immunology research · 2022Article
- Thymic atrophy creates holes in Treg-mediated immuno-regulation via impairment of an antigen-specific clone.Immunology · 2021Article
- The Multiple Roles of B Lymphocytes in the Onset and Treatment of Type 1 Diabetes: Interactions between B Lymphocytes and T Cells.Journal of diabetes research · 2021Review
- Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.Nature communications · 2019Article
- Neutrophil Cytosolic Factor 1 in Dendritic Cells Promotes Autoreactive CD8Frontiers in immunology · 2019Article
- The Neutrophil's Choice: Phagocytose vs Make Neutrophil Extracellular Traps.Frontiers in immunology · 2018Review
- Immunoglobulin M gene association with autoantibody reactivity and type 1 diabetes.Immunogenetics · 2017Article
- DC subset-specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo.The Journal of experimental medicine · 2017Article
- Immune complexes and complexity: investigating mechanisms of renal disease.International urology and nephrology · 2017Article
- Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy.Frontiers in pharmacology · 2017Review
- Immunoregulatory functions of immune complexes in vaccine and therapy.EMBO molecular medicine · 2016Review
- Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
We have developed a model of autoimmunity to investigate autoantibody-mediated cross-presentation of self antigen. RIP-mOVA mice, expressing OVA in pancreatic beta cells, develop severe autoimmune diabetes when given OT-I cells (OVA-specific CD8(+) T cells) and anti-OVA IgG but not when given T cells alone. Anti-OVA IgG is not directly injurious to the islets but rather enhances cross-presentation of apoptotic islet antigen to the OT-I cells, leading to their differentiation into potent effector cells. Antibody-driven effector T cell activation is dependent on the presence of activating Fc receptors for IgG (FcgammaRs) and cross-priming DCs. As a consequence, diabetes incidence and severity was reduced in mice lacking activating FcgammaRs. An intact complement pathway was also required for disease development, as C3 deficiency was also partially protective. C3-deficient animals exhibited augmented T cell priming overall, indicating a proinflammatory role for complement activation after the T cell priming phase. Thus, we show that autoreactive antibody can potently enhance the activation of effector T cells in response to cross-presented self antigen, thereby contributing to T cell-mediated autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.